American cutaneous leishmaniasis (ACL) is a parasitic infectious disease caused by a protozoa of the genus *Leishmania*. It is one of the neglected diseases having greatest impact on public health due to its globalised distribution and limitations in diagnosis, treatment, and control in endemic *foci*. Pentavalent antimony (Sbv) has been the drug of first choice for the treatment of ACL. However, there have been cumulative reports of increased resistance to Sbv in different countries.[@B1] ^,^ [@B2] Individuals refractory to the treatment with Sbv have a greater initial cutaneous lesion and require longer time to heal.[@B3] A previous study has demonstrated the role of wound healing genes in the resolution of CL caused by *Leishmania* spp.[@B4] The friend leukemia integration 1 (*FLI1*) gene, initially identified as a gene controlling susceptibility of mice to *Leishmania major* infection,[@B5] has been also associated with the development of human CL caused by *Leishmania braziliensis*.[@B6] Furthermore, other lesion-healing genes linked to the *FLI1* pathway have been also associated with ACL.[@B7] In this case study, we divided patients into responders and refractories based on their responses to the Sbv therapy to analyse the effects of single-nucleotide variants (SNVs), previously associated with CL, on clinical parameters. One hundred and fifty-nine cases of CL were recruited from an endemic area of Corte de Pedra, Bahia, Brazil. The diagnosis of leishmaniasis was made through a clinical examination, a positive leishmanin skin test (LST) to the soluble *Leishmania* antigen, and by detection of the parasite's DNA through quantitative polymerase chain reaction (qPCR). Ethical approval was obtained from the IRB of the Federal University of Bahia (CEP-UFBA 22/2012) and the Brazilian National Ethical Committee (CONEP: 1258513.1.000.5537) for the use of clinical samples. Informed consent was obtained from the participants. Patients were recruited on admission at the health clinic. Blood samples were collected by venipuncture for genotyping. The patients were followed up until six months after treatment. Clinical data such as the response to treatment, the induration area for the skin test, and number and size of the ulcerated lesions were tabulated for analysis. Patients were classified as responders (controls) and refractories (cases) according to the following criteria: responders - individuals cured of CL after a single course of the Sbv standard treatment (20 mg/kg/day for 20 days) with complete ulcer cicatrisation within 90 days; refractories - patients who needed two or more courses of Sbv or an alternative drug after failure of a single Sbv treatment. Supplementary results of participants have been described in [Table I](#t1){ref-type="table"}. Four SNVs \[*FLI1* (rs7930515), *COL1A1* (rs2586488), *CTGF* (rs6918698), and *SMAD2* (rs1792658)\] were genotyped by the TaqMan^®^ qPCR technology (Thermo Fisher^®^) using predesigned genotyping assays. Analysis of the association between the SNVs and the clinical data was performed by the non-parametric one-way ANOVA Kruskal Wallis or the Mann-Whitney *U* tests using the GraphPad Prism software version 5. P values less than 0.05 were considered statistically significant. From the 159 patients, 54 (33.96%) were the CL refractory cases compared to 105 (66.04%) of the responders. We did not find significant associations between the genetic markers and the response to therapy ([Table II](#t2){ref-type="table"}). However, there was a strong association between the area of induration in the skin test (LST) and the treatment outcome, with the test area being significantly larger in patients responding to Sbv (p = 0.0003), as shown in [Figure](#f){ref-type="fig"} (A). We also observed a strong association between the CC genotype of the *FLI1* gene and the patient's lesion size, with larger lesions observed in the carriers of this genotype (p = 0.017), as shown in [Figure](#f){ref-type="fig"} (B). The CC genotype was less common (C being the minor allele) and the frequencies were 11.3% and 5.1% in clinical cases and in controls, respectively. There were no significant associations between the markers and other parameters analysed.

TABLE IClinical and epidemiological features of cutaneous leishmaniasis (CL) patients according to pentavalent antimony (Sbv) responseClinical and demographic aspectsTherapy responseResponders n = 105Refractories n = 54p valueAge, mean ± SD27.50 ± 15.6527,29 ± 17.180,7920Gender (%)Male67/105(63.80%)32/54 (59.25%)0,6070Number of lesions, median, (IQR)1 (1-2)1 (1-2)0,4659Area of the greatest lesion, mm² (IQR)120,0 (32,5 - 217,0)132,5 (30-412,5)0,2142Area of Montenegro test, mm² (IQR)300 (180 - 419)195,5 (110 - 292,8)0,0003Lower limbs lesions (%)72 (66.74)32 (13.76)0,3080[^2]

TABLE IILogistic regression analysis between single-nucleotide polymorphisms (SNPs) and the pentavalent antimony (Sbv) responseFLI1_rs7930515ORCIpGlobal 2df0.264A/C X C/C0.7480.383-1.4610.397A/A X C/C2.1050.551-8.0410.276Global 1df0.754Allele A1.0800.662-1.7630.755Allele C0.9250.566-1.5090.755likelihood-radio test0.109COL1A1_rs2586488ORCIpGlobal 2df0.946A/G X G/G1.0790.565-2.0580.817A/A X G/G0.9220.319-2.6620.881Global 1df0.994Allele A1.0010.623-1.6080.995Allele G0.9980.621-1.6020.995likelihood-radio test0.739CTGF_rs6918698ORCIpGlobal 2df0.858C/G X G/G0.8250.377-1.8040.631C/C X G/G0.7930.324-1.9400.612Global 1df0.619Allele C0.8930.573-1.3930.620Allele G1.1180.717-1.7430.620likelihood-radio test0.807SMAD2_rs1792658ORCIpGlobal 2df0.554A/C X C/C0.5530.156-1.9610.360A/A X C/C0.7290.212-2.5020.616Global 1df0.900Allele A1.0310.637-1.6670.900Allele C0.9690.599-1.5670.900likelihood-radio test0.280[^3]

\(A\) Induration area (mm) in the skin test of patients classified as refractories or responders according to the treatment with a pentavalent antimony. (B) Lesion size (mm) of patients with leishmaniasis according to the genotypes of the *FLI1* gene.

The LST is one of the most common tests to diagnose CL as well as to confirm active or retrospective leishmaniasis in epidemiological surveys.[@B8] Consistent with our results, a study in Brazil assessed the association between LST and therapeutic response and showed that the patients who did not respond to the treatment had less intense LST reactions than those who achieved clinical cure. For every 10 mm increase in size of the induration area in response to the skin test, there was 26% reduction in the probability of a treatment failure.[@B9] The greater induration area in responding patients may be attributed to their ability to develop an effective response in the early stages of infection by producing proinflammatory cytokines and reducing cytotoxic activity. Exacerbation of the cytotoxic activity has been reported to contribute to the increase in the number and duration of the lesions.[@B10] Previous results have shown that the LST stimulates IFN-γ production[@B11] and this may be reflected in the ability of this group to get cured of the disease with a single course of treatment. Regarding the association between the CC genotype (rs7930515) at the *FLI1* gene and the size of the lesions, the C allele has been previously reported to be associated with an increased susceptibility to the human CL,[@B6] corroborating murine studies on *L. major* resistance.[@B5] In this context, our data supported the role of *FLI1* as an important gene involved in tissue repair mechanisms during human CL since the regulation of polymorphism of this gene is associated with a lesion formation. More functional studies need to be performed to evaluate the mechanisms of gene expression in patients infected with *L. braziliensis* to determine their potential as influencers of the response to treatment and to explore their role as therapeutic targets.

To the physicians and staff of the Health Post of Corte de Pedra for their support in recruiting patients for this study.

Financial support: This work was sponsored by the Programa de Pesquisa para o SUS (030/2014) and the National Institutes of Health (Grant AI 30639).

[^1]: **AUTHORS' CONTRIBUTION:** ASH, LFA and TSL performed the preparation of the samples, genotyping, and collection of the clinical data; PRM participated in the medical care of the patients and reviewed the final version of the manuscript; LCC supervised the laboratory work and undertook the responsibility of data interpretation and preparation of the manuscript. All authors read and approved the final manuscript. The authors declare that they have no commercial or financial relationships that may cause a potential conflict of interest.

[^2]: SD: standard deviation; IQR: interquartile range.
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